|
|
 |
 |
 |
 |
   |
JAN LESCHLYJAN LESCHLY, CEO of Anglo-American drugmaker SmithKline Beecham, spent 1995 digesting $5 billion in acquisitions of managed-care and consumer-medicine markets, then turned his attention to heartburn--by managing the transition of ulcer drug Tagamet, once the world's largest-selling drug, to over-the-counter. SKB's sales could hit $10 billion in '95.
|
Updated June 14, 1997 by bwwebmaster
Copyright 1996, by The McGraw-Hill Companies Inc. All rights reserved.
Terms of Use